BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 25082234)

  • 1. HAUSP compartmentalization in chronic myeloid leukemia.
    Morotti A; Panuzzo C; Crivellaro S; Carrà G; Guerrasio A; Saglio G
    Eur J Haematol; 2015 Apr; 94(4):318-21. PubMed ID: 25082234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BCR-ABL disrupts PTEN nuclear-cytoplasmic shuttling through phosphorylation-dependent activation of HAUSP.
    Morotti A; Panuzzo C; Crivellaro S; Pergolizzi B; Familiari U; Berger AH; Saglio G; Pandolfi PP
    Leukemia; 2014 Jun; 28(6):1326-33. PubMed ID: 24317448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unleashing the Guardian: The Targetable BCR-ABL/HAUSP/PML/PTEN Network in Chronic Myeloid Leukemia.
    Morotti A; Torti D; Carra G; Panuzzo C; Crivellaro S; Taulli R; Fava C; Guerrasio A; Saglio G
    Curr Drug Targets; 2017; 18(4):389-395. PubMed ID: 27291926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCR-ABL promotes PTEN downregulation in chronic myeloid leukemia.
    Panuzzo C; Crivellaro S; Carrà G; Guerrasio A; Saglio G; Morotti A
    PLoS One; 2014; 9(10):e110682. PubMed ID: 25343485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nucleophosmin/B26 regulates PTEN through interaction with HAUSP in acute myeloid leukemia.
    Noguera NI; Song MS; Divona M; Catalano G; Calvo KL; García F; Ottone T; Florenzano F; Faraoni I; Battistini L; Colombo E; Amadori S; Pandolfi PP; Lo-Coco F
    Leukemia; 2013 Apr; 27(5):1037-43. PubMed ID: 23183427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network.
    Song MS; Salmena L; Carracedo A; Egia A; Lo-Coco F; Teruya-Feldstein J; Pandolfi PP
    Nature; 2008 Oct; 455(7214):813-7. PubMed ID: 18716620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non genomic loss of function of tumor suppressors in CML: BCR-ABL promotes IκBα mediated p53 nuclear exclusion.
    Crivellaro S; Panuzzo C; Carrà G; Volpengo A; Crasto F; Gottardi E; Familiari U; Papotti M; Torti D; Piazza R; Redaelli S; Taulli R; Guerrasio A; Saglio G; Morotti A
    Oncotarget; 2015 Sep; 6(28):25217-25. PubMed ID: 26295305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The downregulation of BAP1 expression by BCR-ABL reduces the stability of BRCA1 in chronic myeloid leukemia.
    Dkhissi F; Aggoune D; Pontis J; Sorel N; Piccirilli N; LeCorf A; Guilhot F; Chomel JC; Ait-Si-Ali S; Turhan AG
    Exp Hematol; 2015 Sep; 43(9):775-80. PubMed ID: 26118501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCR-ABL inactivates cytosolic PTEN through Casein Kinase II mediated tail phosphorylation.
    Morotti A; Panuzzo C; Crivellaro S; Carrà G; Fava C; Guerrasio A; Pandolfi PP; Saglio G
    Cell Cycle; 2015; 14(7):973-9. PubMed ID: 25608112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
    Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ
    Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C; Bianchini M; Bengió R; Larripa I
    Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
    Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
    Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of BCR-ABL-Y177-mediated p27kip1 phosphorylation and cytoplasmic localization in enhanced proliferation of chronic myeloid leukemia progenitors.
    Chu S; McDonald T; Bhatia R
    Leukemia; 2010 Apr; 24(4):779-87. PubMed ID: 20200561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation.
    Coluccia AM; Vacca A; Duñach M; Mologni L; Redaelli S; Bustos VH; Benati D; Pinna LA; Gambacorti-Passerini C
    EMBO J; 2007 Mar; 26(5):1456-66. PubMed ID: 17318191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia.
    Roy S; Jørgensen HG; Roy P; Abed El Baky M; Melo JV; Strathdee G; Holyoake TL; Bartholomew C
    Br J Haematol; 2012 May; 157(4):446-56. PubMed ID: 22372463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of BCR/ABL gene expression on the proliferative rate of different subpopulations of haematopoietic cells in chronic myeloid leukaemia.
    Primo D; Flores J; Quijano S; Sanchez ML; Sarasquete ME; del Pino-Montes J; Gaarder PI; Gonzalez M; Orfao A
    Br J Haematol; 2006 Oct; 135(1):43-51. PubMed ID: 16939497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation.
    Massimino M; Consoli ML; Mesuraca M; Stagno F; Tirrò E; Stella S; Pennisi MS; Romano C; Buffa P; Bond HM; Morrone G; Sciacca L; Di Raimondo F; Manzella L; Vigneri P
    Carcinogenesis; 2014 May; 35(5):1132-43. PubMed ID: 24445143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells.
    Andreu EJ; Lledó E; Poch E; Ivorra C; Albero MP; Martínez-Climent JA; Montiel-Duarte C; Rifón J; Pérez-Calvo J; Arbona C; Prósper F; Pérez-Roger I
    Cancer Res; 2005 Apr; 65(8):3264-72. PubMed ID: 15833859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single nucleotide polymorphism in PTEN-Long gene: A risk factor in chronic myeloid leukemia.
    Ferri C; Weich N; Gutiérrez L; De Brasi C; Bengió MR; Zapata P; Fundia A; Larripa I
    Gene; 2019 Apr; 694():71-75. PubMed ID: 30738963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
    Neviani P; Santhanam R; Oaks JJ; Eiring AM; Notari M; Blaser BW; Liu S; Trotta R; Muthusamy N; Gambacorti-Passerini C; Druker BJ; Cortes J; Marcucci G; Chen CS; Verrills NM; Roy DC; Caligiuri MA; Bloomfield CD; Byrd JC; Perrotti D
    J Clin Invest; 2007 Sep; 117(9):2408-21. PubMed ID: 17717597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.